Drug-related hypertension and resistance to antihypertensive treatment: A call for action

Journal of Hypertension

Volumn 29, Issue 12, 2011, Pages 2295-2309

  Rossi, Gian P ^a   Seccia, Teresa M ^a   Maniero, Carmela ^a   Pessina, Achille C ^a  

^a UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

Angiogenesis inhibitors; anti inflammatory drugs; cyclosporine; erythopoietin; iatrogenic hypertension; oestrogens; resistant hypertension; steroids

Indexed keywords

ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANALGESIC AGENT; ANTIDEPRESSANT AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CALCIUM CHANNEL BLOCKING AGENT; CARBENOXOLONE; CLOZAPINE; CYCLOSPORIN; DECONGESTIVE AGENT; DIURETIC AGENT; EPHEDRINE; ERYTHROPOIETIN; GLYCYRRHIZIC ACID; IMMUNOSUPPRESSIVE AGENT; METHYLDOPA; MINERALOCORTICOID ANTAGONIST; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; NEBIVOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; STEROID; TORCETRAPIB; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ALCOHOL CONSUMPTION; ANGIOGENESIS; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DISEASE EXACERBATION; DRUG ABUSE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; GLYCYRRHIZA; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VASOCONSTRICTION;

EID: 81355148579     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32834c465d     Document Type: Review

References (167)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.
2. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
3. Kaplan NM. Resistant hypertension. J Hypertens 2005; 23:1441-1444.
4. Grossman E, Messerli FH. Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 2008; 10:556-566.
5. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 2003; 138:W1-W12.
6. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009; 301:831-841.
7. 2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures. Exp Hematol 1996; 24:392-397.
8. Stichtenoth DO, Marhauer V, Tsikas D, Gutzki FM, Frolich JC. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 2005; 68:2197-2207.
9. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121:289-300.
10. Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993; 153:477-484.
11. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006; 54:282-291.
12. Forman JP, Stampfer MJ, Curhan GC. Nonnarcotic analgesic dose and risk of incident hypertension in US women. Hypertension 2005; 46:500-507.
13. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens 2009; 27:2332-2341.
14. White WB. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 2007; 49:408-418.
15. Conlin PR, Moore TJ, Swartz SL, Barr E, Gazdick L, Fletcher C, et al. Effect of indomethacin on blood pressure lowering by captopril and losartan in hypertensive patients. Hypertension 2000; 36:461-465.
16. Solomon DH, Schneeweiss S, Levin R, Avorn J. Relationship between COX-2 specific inhibitors and hypertension. Hypertension 2004; 44:140-145.
17. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 1999; 96:272-277.
18. Chang IJ, Harris RC. Are all COX-2 inhibitors created equal? Hypertension 2005; 45:178-180.
19. Zhang W, Li JL, Hosaka M, Janz R, Shelton JM, Albright GM, et al. Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings. Proc Natl Acad Sci U S A 2000; 97:9765-9770.
20. Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA 2006; 296:1619-1632.
21. Fored CM, Ejerblad E, Lindblad P, Fryzek JP, Dickman PW, Signorello LB, et al. Acetaminophen, aspirin, and chronic renal failure. N Engl J Med 2001; 345:1801-1808.
22. Salvetti A, Magagna A, Abdel-Haq B, Lenzi M, Giovannetti R. Nifedipine interactions in hypertensive patients. Cardiovasc Drugs Ther 1990; 4 (Suppl 5):963-968.
23. Wilson SL, Poulter NR. The effect of nonsteroidal anti-inflammatory drugs and other commonly used nonnarcotic analgesics on blood pressure level in adults. J Hypertens 2006; 24:1457-1469.
24. Morgan TO, Anderson A, Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000; 13:1161-1167.
25. Houston MC, Weir M, Gray J, Ginsberg D, Szeto C, Kaihlenen PM, et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155:1049-1054.
26. Klassen DK, Jane LH, Young DY, Peterson CA. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 1995; 8:146-153.
27. Armstrong EP, Malone DC. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003; 25:1-18.
28. Whelton A, White WB, Bello AE, Puma JA, Fort JG. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90:959-963.
29. Whelton A. COX-2-specific inhibitors and the kidney: effect on hypertension and oedema. J Hypertens Suppl 2002; 20:S31-S35.
30. White WB, Kent J, Taylor A, Verburg KM, Lefkowith JB, Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002; 39:929-934.
31. Laine L, White WB, Rostom A, Hochberg M. COX-2 selective inhibitors in the treatment of osteoarthritis. Semin Arthritis Rheum 2008; 38:165-187.
32. Gaziano JM. Nonnarcotic analgesics and hypertension. Am J Cardiol 2006; 97:10-16.
33. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. J Am Coll Cardiol 2009; 53:221-231.
34. August P, Oparil S. Hypertension in women. J Clin Endocrinol Metab 1999; 84:1862-1866.
35. Czarnecka D, Kawecka-Jaszcz K, Olszanecka A, Dembinska-Kiec A, Malczewska-Malec M, Zdzienicka A, Guevara I. The effect of hormone replacement therapy on endothelial function in postmenopausal women with hypertension. Med Sci Monit 2004; 10:CR55-CR61.
36. Affinito P, Palomba S, Bonifacio M, Fontana D, Izzo R, Trimarco B, Nappi C. Effects of hormonal replacement therapy in postmenopausal hypertensive patients. Maturitas 2001; 40:75-83.
37. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-333.
38. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007; 297:1465-1477.
39. Grossman E, Messerli FH. High blood pressure. A side effect of drugs, poisons, and food. Arch Intern Med 1995; 155:450-460.
40. Rosenthal T, Oparil S. The effect of antihypertensive drugs on the fetus. J Hum Hypertens 2002; 16:293-298.
41. Gradman AH, Weir MR, Wright M, Bush CA, Keefe DL. Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. J Hum Hypertens 2010; 24:721-729.
42. Hammer F, Stewart PM. Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab 2006; 20:337-353.
43. Rickard AJ, Funder JW, Morgan J, Fuller PJ, Young MJ. Does glucocorticoid receptor blockade exacerbate tissue damage after mineralocorticoid/salt administration? Endocrinology 2007; 148:4829-4835.
44. Jardine AG. Assessing the relative risk of cardiovascular disease among renal transplant patients receiving tacrolimus or cyclosporine. Transpl Int 2005; 18:379-384.
45. Mells G, Neuberger J. Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007; 83:1141-1150.
46. Diaz JM, Gich I, Bonfill X, Sola R, Guirado L, Facundo C, et al. Prevalence evolution and impact of cardiovascular risk factors on allograft and renal transplant patient survival. Transplant Proc 2009; 41:2151-2155.
47. Fellstrom B, Holdaas H, Jardine AG, Nyberg G, Gronhagen-Riska C, Madsen S, et al. Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial. Transplantation 2005; 79:205-212.
48. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82:603-611.
49. Akioka K, Takahara S, Ichikawa S, Yoshimura N, Akiyama T, Ohshima S. Factors predicting long-term graft survival after kidney transplantation: multicenter study in Japan. World J Surg 2005; 29:249-256.
50. Berber I, Aydin C, Yigit B, Kara VM, Yildar M, Duzyol C, et al. Blood pressure and graft outcome in renal transplantation. Transplant Proc 2005; 37:997-998.
51. Legendre C, Campistol JM, Squifflet JP, Burke JT, Sirolimus European Renal Transplant Study Group. Cardiovascular risk factors of sirolimus compared with cyclosporine: early experience from two randomized trials in renal transplantation. Transplant Proc 2003; 35:151S-153S.
52. Reichart B, Meiser B, Vigano M, Rinaldi M, Martinelli L, Yacoub M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results-European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17:775-781.
53. Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18:336-345.
54. Meiser BM, Uberfuhr P, Fuchs A, Schmidt D, Pfeiffer M, Paulus D, et al. Single-center randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of acute myocardial rejection. J Heart Lung Transplant 1998; 17:782-788.
55. Grimm M, Rinaldi M, Yonan NA, Arpesella G, Arizon Del Prado JM, Pulpon LA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients: a large European trial. Am J Transplant 2006; 6:1387-1397.
56. Rossetto A, Bitetto D, Bresadola V, Lorenzin D, Baccarani U, De Anna D, et al. Cardiovascular risk factors and immunosuppressive regimen after liver transplantation. Transplant Proc 2010; 42:2576-2578.
57. Perez MJ, Garcia DM, Taybi BJ, Daga JA, Rey JM, Grande RG, et al. Cardiovascular risk factors after liver transplantation: analysis of related factors. Transplant Proc 2011; 43:739-741.
58. Bendix G, Bjelle A. Adding low-dose cyclosporin A to parenteral gold therapy in rheumatoid arthritis: a double-blind placebo-controlled study. Br J Rheumatol 1996; 35:1142-1149.
59. Marra CA, Esdaile JM, Guh D, Fisher JH, Chalmers A, Anis AH. The effectiveness and toxicity of cyclosporin A in rheumatoid arthritis: longitudinal analysis of a population-based registry. Arthritis Rheum 2001; 45:240-245.
60. Ellis CN, Fradin MS, Messana JM, Brown MD, Siegel MT, Hartley AH, et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, doubleblind trial. N Engl J Med 1991; 324:277-284.
61. Busauschina A, Schnuelle P, van der Woude FJ. Cyclosporine nephrotoxicity. Transplant Proc 2004; 36:229S-233S.
62. Sandborn WJ,Hay JE, Porayko MK,Gores GJ, Steers JL, KromRA,Wiesner RH. Cyclosporine withdrawal for nephrotoxicity in liver transplant recipients does not result in sustained improvement in kidney function and causes cellular and ductopenic rejection. Hepatology 1994; 19:925-932.
63. Venkat-Raman G, Feehally J, Elliott HL, Griffin P, Moore RJ, Olubodun JO, Wilkinson R. Renal and haemodynamic effects of amlodipine and nifedipine in hypertensive renal transplant recipients. Nephrol Dial Transplant 1998; 13:2612-2616.
64. Mourad G, Ribstein J, Mimran A. Converting-enzyme inhibitor versus calcium antagonist in cyclosporine-treated renal transplants. Kidney Int 1993; 43:419-425.
65. del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Pereira P, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998; 68:S135-S139.
66. Calvino J, Lens XM, Romero R, Sanchez-Guisande D. Long-term antiproteinuric effect of Losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000; 15:82-86.
67. Schaefer RM, Leschke M, Strauer BE, Heidland A. Blood rheology and hypertension in hemodialysis patients treated with erythropoietin. Am J Nephrol 1988; 8:449-453.
68. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988; 1:97-100.
69. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am J Physiol 1991; 261:E642-E646.
70. Carlini RG, Dusso AS, Obialo CI, Alvarez UM, Rothstein M. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int 1993; 43:1010-1014.
71. Ioka T, Tsuruoka S, Ito C, Iwaguro H, Asahara T, Fujimura A, Kusano E. Hypertension induced by erythropoietin has a correlation with truncated erythropoietin receptor mRNA in endothelial progenitor cells of hemodialysis patients. Clin Pharmacol Ther 2009; 86:154-159.
72. Hand MF, Haynes WG, Johnstone HA, Anderton JL, Webb DJ. Erythropoietin enhances vascular responsiveness to norepinephrine in renal failure. Kidney Int 1995; 48:806-813.
73. Zhu X, Perazella MA. Nonhematologic complications of erythropoietin therapy. Semin Dial 2006; 19:279-284.
74. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol 2009; 4:470-480.
75. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol 1991; 2:927-936.
76. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group. BMJ 1990; 300:573-578.
77. Tuncel M, Wang Z, Arbique D, Fadel PJ, Victor RG, Vongpatanasin W. Mechanism of the blood pressure-raising effect of cocaine in humans. Circulation 2002; 105:1054-1059.
78. Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr 2009; 155:84-89; 89.e1.
79. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006; 21:92-95.
80. Buitelaar JK, Ramos-Quiroga JA, Casas M, Kooij JJ, Niemela A, Konofal E, et al. Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat 2009; 5:457-466.
81. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. A randomized, placebo-controlled trial of OROS methylpenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 59:829-835.
82. Boellner SW, Stark JG, Krishnan S, Zhang Y. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, D-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: a single-dose, randomized, open-label, crossover study. Clin Ther 2010; 32:252-264.
83. Wilens TE, Spencer TJ, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectr 2005; 10:22-30.
84. Adler LA, Weisler RH, Goodman DW, Hamdani M, Niebler GE. Shortterm effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2009; 70:1652-1661.
85. Findling RL, Childress AC, Krishnan S, McGough JJ. Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectr 2008; 13:614-620.
86. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003; 157:17-25.
87. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008; 117:2407-2423.
88. Fuchs FD, Chambless LE, Whelton PK, Nieto FJ, Heiss G. Alcohol consumption and the incidence of hypertension: the Atherosclerosis Risk in Communities Study. Hypertension 2001; 37:1242-1250.
89. Klatsky AL, Gunderson E. Alcohol and hypertension: a review. J Am Soc Hypertens 2008; 2:307-317.
90. MacMahon S. Alcohol consumption and hypertension. Hypertension 1987; 9:111-121.
91. Kawano Y, Abe H, Kojima S, Ashida T, Yoshida K, Imanishi M, et al. Acute depressor effect of alcohol in patients with essential hypertension. Hypertension 1992; 20:219-226.
92. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42:1206-1252.
93. Taylor B, Irving HM, Baliunas D, Roerecke M, Patra J, Mohapatra S, Rehm J. Alcohol and hypertension: gender differences in dose-response relationships determined through systematic review and meta-analysis. Addiction 2009; 104:1981-1990.
94. Sarafidis PA, Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52:1749-1757.
95. Spence JD. Physiologic tailoring of treatment in resistant hypertension. Curr Cardiol Rev 2010; 6:119-123.
96. Savica V, Bellinghieri G, Kopple JD. The effect of nutrition on blood pressure. Annu Rev Nutr 2010; 30:365-401.
97. Stewart SH, Oroszi G, Randall PK, Anton RF. COMT genotype influences the effect of alcohol on blood pressure: results from the COMBINE study. Am J Hypertens 2009; 22:87-91.
98. Prineas RJ, Jacobs DR Jr, Crow RS, Blackburn H. Coffee, tea and VPB. J Chronic Dis 1980; 33:67-72.
99. Klatsky AL, Friedman GD, Armstrong MA. Coffee use prior to myocardial infarction restudied: heavier intake may increase the risk. Am J Epidemiol 1990; 132:479-488.
100. Periti M, Salvaggio A, Quaglia G, Di Marzio L. Coffee consumption and blood pressure: an Italian study. Clin Sci (Lond) 1987; 72:443-447.
101. Stensvold I, Tverdal A, Foss OP. The effect of coffee on blood lipids and blood pressure. Results from a Norwegian cross-sectional study, men and women, 40-42 years. J Clin Epidemiol 1989; 42:877-884.
102. Salvaggio A, Periti M, Miano L, Zambelli C. Association between habitual coffee consumption and blood pressure levels. J Hypertens 1990; 8:585-590.
103. Lancaster T, Muir J, Silagy C. The effects of coffee on serum lipids and blood pressure in a UK population. J R Soc Med 1994; 87:506-507.
104. Hino A, Adachi H, Enomoto M, Furuki K, Shigetoh Y, Ohtsuka M, et al. Habitual coffee but not green tea consumption is inversely associated with metabolic syndrome: an epidemiological study in a general Japanese population. Diabetes Res Clin Pract 2007; 76:383-389.
105. Wakabayashi K, Kono S, Shinchi K, Honjo S, Todoroki I, Sakurai Y, et al. Habitual coffee consumption and blood pressure: a study of self-defense officials in Japan. Eur J Epidemiol 1998; 14:669-673.
106. Lewis CE, Caan B, Funkhouser E, Hilner JE, Bragg C, Dyer A, et al. Inconsistent associations of caffeine-containing beverages with blood pressure and with lipoproteins. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 1993; 138:502-507.
107. Uiterwaal CS, Verschuren WM, Bueno-de-Mesquita HB, Ocke M, Geleijnse JM, Boshuizen HC, et al. Coffee intake and incidence of hypertension. Am J Clin Nutr 2007; 85:718-723.
108. Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA 2005; 294:2330-2335.
109. Jenner DA, Puddey IB, Beilin LJ, Vandongen R. Lifestyle- and occupationrelated changes in blood pressure over a six-year period in a cohort of working men. J Hypertens Suppl 1988; 6:S605-S607.
110. Narkiewicz K, Maraglino G, Biasion T, Rossi G, Sanzuol F, Palatini P. Interactive effect of cigarettes and coffee on daytime systolic blood pressure in patients with mild essential hypertension. HARVEST Study Group (Italy). Hypertension Ambulatory Recording VEnetia STudy. J Hypertens 1995; 13:965-970.
111. Geleijnse JM. Habitual coffee consumption and blood pressure: an epidemiological perspective. Vasc Health Risk Manag 2008; 4:963-970.
112. Robertson D, Frolich JC, Carr RK, Watson JT, Hollifield JW, Shand DG, Oates JA. Effects of caffeine on plasma renin activity, catecholamines and blood pressure. N Engl J Med 1978; 298:181-186.
113. Myers MG. Effects of caffeine on blood pressure. Arch Intern Med 1988; 148:1189-1193.
114. Nurminen ML, Niittynen L, Korpela R, Vapaatalo H. Coffee, caffeine and blood pressure: a critical review. Eur J Clin Nutr 1999; 53:831-839.
115. Umemura T, Ueda K, Nishioka K, Hidaka T, Takemoto H, Nakamura S, et al. Effects of acute administration of caffeine on vascular function. Am J Cardiol 2006; 98:1538-1541.
116. Ammon HP, Bieck PR, Mandalaz D, Verspohl EJ. Adaptation of blood pressure to continuous heavy coffee drinking in young volunteers. A double-blind crossover study. Br J Clin Pharmacol 1983; 15:701-706.
117. Bonita JS, Mandarano M, Shuta D, Vinson J. Coffee and cardiovascular disease: in vitro, cellular, animal, and human studies. Pharmacol Res 2007; 55:187-198.
118. Mazur WM, Wahala K, Rasku S, Salakka A, Hase T, Adlercreutz H. Lignan and isoflavonoid concentrations in tea and coffee. Br J Nutr 1998; 79:37-45.
119. Diaz-Rubio ME, Saura-Calixto F. Dietary fiber in brewed coffee. J Agric Food Chem 2007; 55:1999-2003.
120. Grossman E, Messerli FH. Management of drug-induced and iatrogenic Hypertension. In: Izzo Jr JL, Black HR, editors. Hypertension primer. 3rd ed. Dallas, TX: Lippincott Williams & Wilkins; 2003. pp. 516-519.
121. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58:1172-1176.
122. Henderson DC, Daley TB, Kunkel L, Rodrigues-Scott M, Koul P, Hayden D. Clozapine and hypertension: a chart review of 82 patients. J Clin Psychiatry 2004; 65:686-689.
123. Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of diphenhydramine and modafinil on arousal and autonomic functions in healthy volunteers. J Psychopharmacol 2007; 21:567-578.
124. Taneja I, Diedrich A, Black BK, Byrne DW, Paranjape SY, Robertson D. Modafinil elicits sympathomedullary activation. Hypertension 2005; 45:612-618.
125. Roth T, Schwartz JR, Hirshkowitz M, Erman MK, Dayno JM, Arora S. Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med 2007; 3:595-602.
126. Eccles R. Substitution of phenylephrine for pseudoephedrine as a nasal decongeststant. An illogical way to control methamphetamine abuse. Br J Clin Pharmacol 2007; 63:10-14.
127. Thomas SH, Clark KL, Allen R, Smith SE. A comparison of the cardiovascular effects of phenylpropanolamine and phenylephrine containing proprietary cold remedies. Br J Clin Pharmacol 1991; 32:705-711.
128. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96:1788-1795.
129. Verheul HM, Pinedo HM. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007; 7:475-485.
130. Board RE, Thistlethwaite FC, Hawkins RE. Antiangiogenic therapy in the treatment of advanced renal cell cancer. Cancer Treat Rev 2007; 33:1-8.
131. Humphreys BD, Atkins MB. Rapid development of hypertension by sorafenib: toxicity or target? Clin Cancer Res 2009; 15:5947-5949.
132. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009; 20:807-815.
133. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49:186-193.
134. Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007; 25:3559.
135. Ozcan C, Wong SJ, Hari P. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980-982; discussion 980-982.
136. Jia H, Bagherzadeh A, Bicknell R, Duchen MR, Liu D, Zachary I. Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. J Biol Chem 2004; 279:36148-36157.
137. Hood JD, Meininger CJ, Ziche M, Granger HJ. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells. Am J Physiol 1998; 274:H1054-H1058.
138. Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004; 7:335-345.
139. Veronese ML, Mosenkis A, Flaherty KT, Gallagher M, Stevenson JP, Townsend RR, O'Dwyer PJ. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24:1363-1369.
140. Okuda Y, Tsurumaru K, Suzuki S, Miyauchi T, Asano M, Hong Y, et al. Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci 1998; 63:477-484.
141. Matsuura A, Kawashima S, Yamochi W, Hirata K, Yamaguchi T, Emoto N, Yokoyama M. Vascular endothelial growth factor increases endothelinconverting enzyme expression in vascular endothelial cells. Biochem Biophys Res Commun 1997; 235:713-716.
142. Mourad JJ, des Guetz G, Debbabi H, Levy BI. Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19:927-934.
143. Steeghs N, Gelderblom H, Roodt JO, Christensen O, Rajagopalan P, Hovens M, et al. Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor. Clin Cancer Res 2008; 14:3470-3476.
144. Dincer M, Altundag K. Angiotensin-converting enzyme inhibitors for bevacizumab-induced hypertension. Ann Pharmacother 2006; 40:2278-2279.
145. Luscher TF, Spieker LE, Noll G, Cosentino F. Vascular effects of newer cardiovascular drugs: focus on nebivolol and ACE-inhibitors. J Cardiovasc Pharmacol 2001; 38 (Suppl 3):S3-S11.
146. Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta 2007; 381:26-31.
147. Amsterdam JD, Garcia-Espana F, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Beasley C. Blood pressure changes during short-term fluoxetine treatment. J Clin Psychopharmacol 1999; 19:9-14.
148. Bortolato M, Chen K, Shih JC. Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv Drug Deliv Rev 2008; 60:1527-1533.
149. Licht CM, de Geus EJ, Seldenrijk A, van Hout HP, Zitman FG, van Dyck R, Penninx BW. Depression is associated with decreased blood pressure, but antidepressant use increases the risk for hypertension. Hypertension 2009; 53:631-638.
150. Korzets A, Floro S, Ori Y, Weizer N, Gruzman C. Clomipramineinduced pheochromocytoma crisis: a near fatal complication of a tricyclic antidepressant. J Clin Psychopharmacol 1997; 17:428-430.
151. Ferguson KL. Imipramine-provoked paradoxical pheochromocytoma crisis: a case of cardiogenic shock. Am J Emerg Med 1994; 12:190-192.
152. Thase ME. Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients. J Clin Psychiatry 1998; 59:502-508.
153. Khurana RN, Baudendistel TE. Hypertensive crisis associated with venlafaxine. Am J Med 2003; 115:676-677.
154. Rossi GP, Rizzoni D. Therapy: raising HDL cholesterol levels: a flight of Icarus? Nat Rev Endocrinol 2010; 6:245-246.
155. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356:1304-1316.
156. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357:2109-2122.
157. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008; 154:1465-1473.
158. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, et al. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL treatment Strategy in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010; 55:2721-2726.
159. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15:2001-2010.
160. Seaberg EC, Munoz A, Lu M, Detels R, Margolick JB, Riddler SA, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS 2005; 19:953-960.
161. Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis 2003; 22:731-736.
162. Palacios R, Santos J, Garcia A, Castells E, Gonzalez M, Ruiz J, Marquez M. Impact of highly active antiretroviral therapy on blood pressure in HIVinfected patients. A prospective study in a cohort of naive patients. HIV Med 2006; 7:10-15.
163. Crane HM, Van Rompaey SE, Kitahata MM. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 2006; 20:1019-1026.
164. Grandominico JM, Fichtenbaum CJ. Short-term effect of HAART on blood pressure in HIV-infected individuals. HIV Clin Trials 2008; 9:52-60.
165. De Socio GV, Schillaci G. Hypertension in HIV patients. AIDS 2006; 20:1682-1683.
166. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. J Hypertens 2003; 21:1377-1382.
167. Wilson SL, Scullard G, Fidler SJ, Weber JN, Poulter NR. Effects of HIV status and antiretroviral therapy on blood pressure. HIV Med 2009; 10:388-394.